Takeda

News

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Digital

How pharma and start-ups are working together for AI success

At the PharmStars Pharmtech Innovation Summit in Boston, start-up founders and pharma executives shared the stage to share lessons on AI deployment.

News

Jury finds Takeda liable for $885m in pay-for-delay lawsuit

Takeda is on the hook for $885m damages – which could rise to $2.5bn – in a suit claiming it paid a rival to delay the launch of a generic competitor.

News

Man yawning, covering his mouth with his hand

FDA kicks off review of Takeda's narcolepsy hopeful

The FDA has started a priority review of Takeda's oveporexton for sleep disorder narcolepsy, setting up a decision in the third quarter of the year.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

How pharma and start-ups are working together for AI success

Jury finds Takeda liable for $885m in pay-for-delay lawsuit

FDA kicks off review of Takeda's narcolepsy hopeful

Takeda signs $1.7bn AI alliance with Iambic

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Takeda

Editor's Picks